The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas

S. Nag, D. Shasha, N. Janjan, Ivy A Petersen, M. Zaider

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Purpose: This report presents the American Brachytherapy Society (ABS) guidelines for the use of brachytherapy for patients with soft tissue sarcoma. Methods and Materials: Members of the ABS with expertise in soft tissue sarcoma formulated brachytherapy guidelines based upon their clinical experience and a review of the literature. The Board of Directors of the ABS approved the final report. Results: Brachytherapy used alone or in combination with external beam irradiation is an established means of safely providing adjuvant local treatment after resection for soft tissue sarcomas in adults and in children. Brachytherapy options include low dose rate techniques with iridium 192 or iodine 125, fractionated high dose rate brachytherapy, or intraoperative high dose rate therapy. Recommendations are made for patient selection, techniques, dose rates, and dosages. Complications and possible interventions to minimize their occurrence and severity are reviewed. Conclusion: Brachytherapy represents an effective means of enhancing the therapeutic ratio, offering both biologic and dosimetric advantage in the treatment of patients with soft tissue sarcoma. The treatment approach used depends upon the institution, physician expertise, and the clinical situation. Guidelines are established for the use of brachytherapy in the treatment of soft tissue sarcomas in adults and in children. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose-reporting policies. These guidelines will be modified, as further clinical results become available.

Original languageEnglish (US)
Pages (from-to)1033-1043
Number of pages11
JournalInternational Journal of Radiation Oncology Biology Physics
Volume49
Issue number4
DOIs
StatePublished - Mar 15 2001

Fingerprint

Brachytherapy
recommendations
Sarcoma
cancer
dosage
Guidelines
iodine 125
Therapeutics
physicians
iridium
Iridium
therapy
occurrences
Iodine
Patient Selection
irradiation
Physicians

Keywords

  • Brachytherapy
  • Pediatric sarcoma
  • Recurrence
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas. / Nag, S.; Shasha, D.; Janjan, N.; Petersen, Ivy A; Zaider, M.

In: International Journal of Radiation Oncology Biology Physics, Vol. 49, No. 4, 15.03.2001, p. 1033-1043.

Research output: Contribution to journalArticle

@article{687f1fc267bb48e58276ef7b87509256,
title = "The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas",
abstract = "Purpose: This report presents the American Brachytherapy Society (ABS) guidelines for the use of brachytherapy for patients with soft tissue sarcoma. Methods and Materials: Members of the ABS with expertise in soft tissue sarcoma formulated brachytherapy guidelines based upon their clinical experience and a review of the literature. The Board of Directors of the ABS approved the final report. Results: Brachytherapy used alone or in combination with external beam irradiation is an established means of safely providing adjuvant local treatment after resection for soft tissue sarcomas in adults and in children. Brachytherapy options include low dose rate techniques with iridium 192 or iodine 125, fractionated high dose rate brachytherapy, or intraoperative high dose rate therapy. Recommendations are made for patient selection, techniques, dose rates, and dosages. Complications and possible interventions to minimize their occurrence and severity are reviewed. Conclusion: Brachytherapy represents an effective means of enhancing the therapeutic ratio, offering both biologic and dosimetric advantage in the treatment of patients with soft tissue sarcoma. The treatment approach used depends upon the institution, physician expertise, and the clinical situation. Guidelines are established for the use of brachytherapy in the treatment of soft tissue sarcomas in adults and in children. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose-reporting policies. These guidelines will be modified, as further clinical results become available.",
keywords = "Brachytherapy, Pediatric sarcoma, Recurrence, Soft tissue sarcoma",
author = "S. Nag and D. Shasha and N. Janjan and Petersen, {Ivy A} and M. Zaider",
year = "2001",
month = "3",
day = "15",
doi = "10.1016/S0360-3016(00)01534-0",
language = "English (US)",
volume = "49",
pages = "1033--1043",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas

AU - Nag, S.

AU - Shasha, D.

AU - Janjan, N.

AU - Petersen, Ivy A

AU - Zaider, M.

PY - 2001/3/15

Y1 - 2001/3/15

N2 - Purpose: This report presents the American Brachytherapy Society (ABS) guidelines for the use of brachytherapy for patients with soft tissue sarcoma. Methods and Materials: Members of the ABS with expertise in soft tissue sarcoma formulated brachytherapy guidelines based upon their clinical experience and a review of the literature. The Board of Directors of the ABS approved the final report. Results: Brachytherapy used alone or in combination with external beam irradiation is an established means of safely providing adjuvant local treatment after resection for soft tissue sarcomas in adults and in children. Brachytherapy options include low dose rate techniques with iridium 192 or iodine 125, fractionated high dose rate brachytherapy, or intraoperative high dose rate therapy. Recommendations are made for patient selection, techniques, dose rates, and dosages. Complications and possible interventions to minimize their occurrence and severity are reviewed. Conclusion: Brachytherapy represents an effective means of enhancing the therapeutic ratio, offering both biologic and dosimetric advantage in the treatment of patients with soft tissue sarcoma. The treatment approach used depends upon the institution, physician expertise, and the clinical situation. Guidelines are established for the use of brachytherapy in the treatment of soft tissue sarcomas in adults and in children. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose-reporting policies. These guidelines will be modified, as further clinical results become available.

AB - Purpose: This report presents the American Brachytherapy Society (ABS) guidelines for the use of brachytherapy for patients with soft tissue sarcoma. Methods and Materials: Members of the ABS with expertise in soft tissue sarcoma formulated brachytherapy guidelines based upon their clinical experience and a review of the literature. The Board of Directors of the ABS approved the final report. Results: Brachytherapy used alone or in combination with external beam irradiation is an established means of safely providing adjuvant local treatment after resection for soft tissue sarcomas in adults and in children. Brachytherapy options include low dose rate techniques with iridium 192 or iodine 125, fractionated high dose rate brachytherapy, or intraoperative high dose rate therapy. Recommendations are made for patient selection, techniques, dose rates, and dosages. Complications and possible interventions to minimize their occurrence and severity are reviewed. Conclusion: Brachytherapy represents an effective means of enhancing the therapeutic ratio, offering both biologic and dosimetric advantage in the treatment of patients with soft tissue sarcoma. The treatment approach used depends upon the institution, physician expertise, and the clinical situation. Guidelines are established for the use of brachytherapy in the treatment of soft tissue sarcomas in adults and in children. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose-reporting policies. These guidelines will be modified, as further clinical results become available.

KW - Brachytherapy

KW - Pediatric sarcoma

KW - Recurrence

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0035869738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035869738&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(00)01534-0

DO - 10.1016/S0360-3016(00)01534-0

M3 - Article

VL - 49

SP - 1033

EP - 1043

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -